In what some are calling "a world 1st," researchers reported some success in treating severe anorexia patients via implanted electrodes that delivered electrical energy to the regions of the brain associated with emotion.
The study enrolled 6 patients to receive the experimental treatment, reporting that 3 of the 6 achieved weight gain and 4 of the 6 reported changes in mood, anxiety, control over their urges to binge and purge and other symptoms associated with anorexia.
Medtronic (NYSE:MDT) implanted its CoreValve transcatheter aortic valve implantation system into the first patient in a Japanese clinical trial of the device’s safety and effectiveness.
The CoreValve system is a minimally invasive treatment option for patients with severe heart disease who are at high risk or unable to undergo open-heart surgery.
Brainsway Ltd.’s (PINK:BRSYF) transcranial magnetic stimulation device won Israeli Ministry of Health approval to treat major depression, bipolar disorder and negative impairment in schizophrenia patients.
The approval clears Jerusalem-based Brainsway to sell the non-invasive TMS device, which delivers brief magnetic pulses to the brain, to four medical centers specializing in mental disorders.
JERUSALEM, Oct. 3, 2011 (GLOBE NEWSWIRE) — Brainsway Ltd. (TASE:BRIN) is pleased to announce that it has received approval from Israel’s Ministry of Health to market and sell the Company’s Deep TMS device to four medical centers for the treatment of major depression, bipolar disorder and negative symptoms and cognitive impairment in schizophrenic patients.
Uzi Sofer, Brainsway’s Chief Executive Officer, commented, “We are very pleased to receive this vote of confidence in the Deep TMS technology from our homeland’s regulatory authority. We are now working to update indications with the Israeli Ministry of Health to bring them more in line with the approvals that we’ve already received in Europe.”
About Brainsway Inc.